Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing
Source: SeekingAlpha
2026-05-02 03:20:18 ET
If you vaguely follow big pharma, then you have probably heard of something called a patent cliff, which is when a company has multiple patents expiring within a short timeframe. Though patent expiration may be better for the consumer, it essentially means that any company can now manufacture and sell patented drugs that were once exclusive to one company. This undercuts the pricing power of the company that had the initial patent, destroying profit margins for that product....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing
Cabaletta Bio Inc.
NASDAQ: CABA
CABA Trading
-4.26% G/L:
$3.26 Last:
2,211,724 Volume:
$3.48 Open:
CABA Latest News
June 03, 2026 07:00:00 am
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
May 14, 2026 07:05:00 am
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
CABA Stock Data
$250,770,856
85,435,369
1.33%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
